Efficient CRISPR/HDR-mediated knock-in system and method of use

Patent metadata

Field	Value
Publication number	US-11530424-B1
Application number	US-201916587405-A
Country	US
Kind code	B1
Filing date	Sep 30, 2019
Priority date	Sep 18, 2015
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

The clustered regularly interspaced short palindromic repeat (CRISPR) gene editing technique, based on the non-homologous end-joining (NHEJ) repair pathway, can efficiently generate gene knockouts of variably sizes. More precise genome editing, either the insertion or deletion of a desired fragment, can be done by combining the homology-directed-repair (HDR) pathway with CRISPR cleavage. HDR-mediated gene knock-in experiments are inefficient, with no reports of successful gene knock-in with DNA fragments larger than 4 kb. Targeted insertion of large DNA fragments (7.4 and 5.8 kb) into the genomes of mouse embryonic stem cells and zygotes, respectively, using the CRISPR/HDR technique without NHEJ inhibitors was performed and indicate that CRISPR/HDR without NHEJ inhibitors can result in highly efficient gene knock-in, equivalent to CRISPR/HDR with NHEJ inhibitors. Although NHEJ is the dominant repair pathway associated with CRISPR-mediated double-strand breaks (DSBs), and biallelic gene knock-ins are common, NHEJ and biallelic gene knock-ins were not detected.

First claim

What is claimed is:

1. A method of genome editing to knock in a large DNA fragment into a target gene of a host in the absence of a non-homologous end joining (NHEJ) inhibitor, comprising:
providing at least one clustered regularly interspaced short palindromic repeat (CRISPR) system comprising
a first plasmid nucleic acid vector comprising
a DNA encoding a single guide RNA (sgRNA) wherein the single guide RNA comprising
a CRISPR-related (crRNA) segment complementary to a target sequence in the target gene of the host; and
a trans-activating CRISPR-related sequence (tracrRNA) required for function of a CRISPR endonuclease; and

a DNA encoding the CRISPR endonuclease wherein the CRISPR endonuclease is Cas9;

a second plasmid nucleic acid vector comprising
a donor DNA sequence comprising
a DNA fragment of at least 4 kb in length wherein the DNA fragment replaces the target sequence in the target gene of the host or is inserted into a target site in the target gene of the host; and
two homologous arms with each arm flanking opposing sides of the DNA fragment wherein each of the homologous arms is between 3.4 kb and 9 kb in size;

inserting the at least one CRISPR system into a cell wherein the sgRNA guides the CRISPR endonuclease to a cleavage site in the target DNA sequence of the target gene of the host and the CRISPR endonuclease introduces a double stranded break in the target DNA sequence in the target gene of the host; and
allowing the cell to undergo homology-directed-repair using the two homologous arms flanking the DNA fragment to knock in the DNA fragment at the cleavage site of the target DNA sequence in the target gene of the host in the absence of a non-homologous end joining (NHEJ) inhibitor.

2. The method of claim 1 , wherein a concentration of the sgRNA, of the CRISPR endonuclease, and the donor DNA is about one fourth of a standard concentration.

3. The method of claim 1 , wherein the at least one CRISPR system is inserted into the cell by electroporation or microinjection.

4. The method of claim 3 , wherein the CRISPR insertion further comprises:
providing a microinjection buffer;
mixing the CRISPR system in the microinjection buffer to form a microinjection solution; and
injecting the microinjection solution into the cell.

5. The method of claim 4 , wherein the cell is a zygote or stem cell.

6. A method of genome editing to knock in a large DNA fragment into a target gene of a host in the absence of a non-homologous end joining (NHEJ) inhibitor, comprising:
providing at least one clustered regularly interspaced short palindromic repeat (CRISPR) system comprising
a first nucleic acid vector comprising
a DNA encoding a single guide RNA (sgRNA); and
a DNA encoding a CRISPR endonuclease;

a second nucleic acid vector comprising
a donor DNA sequence comprising
a DNA fragment of at least 4 kb in length; and
two homologous arms with each arm flanking opposing sides of the DNA fragment wherein each of the homologous arms is between 3.4 kb and 9 kb in size; and

inserting the at least one CRISPR system into a cell; and
allowing the cell to undergo homology-directed-repair using the two homologous arms flanking the DNA fragment to knock in the DNA fragment at a cleavage site in the target DNA sequence in the target gene of the host in the absence of the non-homologous end joining (NHEJ) inhibitor.

7. The method of claim 6 , wherein a concentration of the sgRNA, of the CRISPR endonuclease, and the donor DNA is about one fourth of a standard concentration.

8. The method of claim 6 , wherein the CRISPR endonuclease is Cas9 or Cpf1.

Assignees

• Wang Jia Wang
• Lockey Richard F
• Univ South Florida
• United States Dept Of Veterans Affairs

Inventors

• Wang Jia-Wang
• Lockey Richard F

Classifications

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• C12N15/907 Primary

  in mammalian cells · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N15/85

  for animal cells · CPC title

• C12N15/102

  Mutagenizing nucleic acids · CPC title